Mineralocorticoid receptor antagonists in atrial fibrillation: a new class of antiarrhythmic drugs?

Condorhuaman J.A.O. · Revista Medica Herediana (2024) · DOI: 10.20453/rmh.v35i2.5245

Resumen

Mineralocorticoid receptor antagonists (MRAs) are beneficial in certain diseases. Results from multiple clinical trials support the indication for this class of drugs as an alternative for the management of atrial fibrillation. This review aims to show the evidence that supports the recommendation. © El autor © Revista Médica Herediana.

Instituciones: Universidad Andina del Cusco